CD5 and diffuse large B-cell lymphoma: The survival of patients with CD5-positive DLBCL was significantly poorer thanthat of patients with T-cell marker-negative DLBCL (Figures 3: 5-year time to progression (TTP), 47% vs. 73%, respectively, p < 0.001; 5-year disease specific survival (DSS), 63% vs. 82%, respectively, p = 0.03).